Genmab — Marts 2021
-
Stadig ikke nogen, der er kommet forbi recepttallene?
-
Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits https://jasn.asnjournals.org/content/early/2021/03/05/ASN.2020101541
-
God morgen.
-
Asien: Stigende renter give nervøsitet i Asien og rammer særligt tech https://www.proinvestor.com/investornyt/672892/asien-stigende-renter-give-
nervositet-i-asien-og-rammer-saerligt-tech -
Tirsdagens danske avisuddrag med Topdanmark, Nordea og Finanstilsynethttps://www.proinvestor.com/investornyt/672894/tirsdagens-danske-avisuddrag-med-topdanmark-nordea-og-finanstilsynet
-
-
Morn - læste lige en dejlig udtalelse om ledelser/selskaber der tænker vækst og investering: “ Jeg mener, der er brug for mere af den slags ledelse, i stedet for dem der fokuserer på udbytter og aktietilbagekøb, for det er ligegyldigt. Invester i vækst,” siger Peter Garnry.”
-
-
-
· Kesimpta's impact on Ocrevus has been minimal and potential 'off-label' use in primary progressive MS (PPMS) is seen as marginal
· KOL highlights that MS field has moved towards earlier adoption of aggressive B-cell depletion therapies with decreased prescribing of oral agents expected in the future
-
Hæh - ofatumumabs smertehistorie er ikke overstået endnu...
-
Det passer vel meget godt med EL’s oplysning om Q4 salg på usd 14m
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind